MedPath

Albiglutide

Generic Name
Albiglutide
Drug Type
Biotech
CAS Number
782500-75-8
Unique Ingredient Identifier
5E7U48495E

Overview

Albiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide was approved on April 15, 2014 by the FDA.

Background

Albiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide was approved on April 15, 2014 by the FDA.

Indication

用于2型糖尿病成年患者,作为饮食和运动的辅助疗法以改善血糖控制。不推荐用于饮食和运动控制不佳患者的一线治疗。

Associated Conditions

  • Type 2 Diabetes Mellitus

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath